Shares of Guangzhou Innogen Pharmaceutical Group (HKG:2591) soared an astounding 288.65% as they began trading on the Hong Kong Stock Exchange on Friday. The dramatic surge reflects intense investor enthusiasm for the company's focus on the booming glucagon-like peptide-1 receptor agonist (GLP-1) drug market.

Innogen Pharma's successful initial public offering (IPO) raised HK$634.7 million in net proceeds. The company priced its 36,556,400 H-shares at HK$18.68 each, with the Hong Kong public offer portion being 5,341.66 times oversubscribed. The international offering was 10.67 times subscribed, highlighting the strong demand from both local and global investors. Notably, cornerstone investors, including June Star Global and Ginkgo Capital Global Fund, were allotted about 11.49% of the global offering.

The exceptional market response to Innogen-B's debut comes amid a flourishing global GLP-1 drug market. In 2024, GLP-1 medications dominated global pharmaceutical sales rankings with revenues exceeding $50 billion. The first quarter of 2025 alone saw global transaction volume in related sectors reach $13.024 billion, underscoring the rapid growth and immense potential of the weight-loss drug market. Innogen-B's focus on GLP-1 drug development has clearly resonated with investors seeking exposure to this lucrative sector.

The successful listing of Innogen-B, achieving a market capitalization exceeding HK$32.4 billion post-surge, signals strong market confidence in the company's prospects and the broader GLP-1 drug sector. As the global battle against diabetes and obesity intensifies, Innogen-B's spectacular debut positions it as a key player to watch in the competitive and fast-evolving pharmaceutical landscape.